SIMSCALE
15.2.2018 11:18:06 CET | Business Wire | Press release
SimScale GmbH (“SimScale”), the provider of the full-cloud engineering simulation platform, today announced a collaboration with Siemens PLM Software and Tech Soft 3D to optimize the simulation workflow through better CAD model handling. SimScale will bring the benefits of Siemens’ Parasolid® software and HOOPS Exchange to a browser-based CAE.
The latest release of SimScale, available shortly, will integrate Parasolid and HOOPS Exchange to enable a more convenient and seamless simulation workflow, while at the same time further increasing simulation result accuracy—both in FEA and CFD.
“Our vision at SimScale is to enable every designer and engineer to take full advantage of engineering simulation—independent of budget, hardware and know-how. This includes seamless interoperability with the customer’s CAD system as well as fast, robust and accurate preparation of CAD data to achieve reliable simulation results quickly. Integrating Parasolid and HOOPS Exchange will help us achieve just that.” said David Heiny, CEO and co-founder of SimScale.
Parasolid is the industry-leading 3D geometric modeling component for computer-aided design, manufacturing and engineering analysis (CAD/CAM/CAE) solutions, while HOOPS Exchange is the leading CAD translation software development kit (SDK). The suppliers of both solutions are continuously innovating in the field of 3d modeling, in order to meet constantly evolving industry trends. This includes building best-in-class solutions for the growing number of cloud-based applications.
“This latest implementation of Parasolid in a cloud-based application will enable engineers to simulate, test and modify 3D models using only a web browser,” says Jim Rusk, chief technology officer, Siemens PLM Software. “In selecting Parasolid, Simscale also obtains translation-free interoperability with hundreds of other applications that integrate Parasolid to design, edit and exchange high-precision 3D models based on the Parasolid XT data format.”
“With the rapid pace of technology advancement, our partners continue to push the boundaries of what’s possible for engineering software development in web technology—our mission is to help them create the best engineering applications in the quickest, easiest way possible,” said Gavin Bridgeman, chief technology officer at Tech Soft 3D. “We are excited about the partnership with SimScale and in particular enabling their customers to bring their CAD data, be it Parasolid-based or otherwise, effortlessly and accurately to the SimScale platform.”
Since the official launch in 2013, SimScale is challenging the “status quo” of the traditional computer-aided engineering (CAE) software market by offering a fully cloud-based engineering simulation solution with zero hardware and software footprint, available at the fraction of the price of its competitors.
“SimScale users have the benefit of a fully collaborative, professional-grade CAE tool covering multiple simulation types powered by unlimited computing power—all via a standard web browser.” said Jon Stevenson, Board Member of SimScale. “The fact that SimScale runs in the cloud enables a broad range of advantages such as multi-user access, collaboration, easy scaling of computing resources, and automated maintenance. ”
SimScale offers a Community plan which is free to all users willing to share their projects publicly. The Professional plan can be tested via a free 14-day trial. Getting started with the trial version only takes a few minutes and requires just a standard web browser.
To learn more about the SimScale pricing plans, visit: https://www.simscale.com/product/pricing/
Note: Parasolid is a trademark or registered trademark of Siemens Product Lifecycle Management Software Inc. or its subsidiaries in the United States and in other countries.
About SimScale:
SimScale is a provider of powerful online 3D simulation technology which is changing the way engineers, designers and students design products. With a founding team of mechanical engineers, computer scientists and mathematicians, SimScale’s goal is to enable everyone to design better products faster and more cost-efficiently by putting engineering simulation tools into the hands of a broader audience. For more information, visit www.simscale.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20180215005476/en/
Contact:
SimScale
Agata Krzysztofik
Chief Marketing Officer
+49-89-8091327-65
agata@simscale.com
or
Tech
Soft 3D
Angela Simoes
PR Manager
415-302-2934
angela@techsoft3d.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom